论文部分内容阅读
目的探讨康复新液联合泮托拉唑三联疗法治疗消化性溃疡(PU)的临床疗效。方法选取2015年9—12月上饶市人民医院收治的PU患者100例。随机分为对照组与干预组,各50例。对照组予以泮托拉唑、克拉霉素、阿莫西林治疗,干预组在对照组基础上给予康复新液治疗。比较两组患者PU临床症状疗效、胃镜复查PU愈合治疗情况、幽门螺杆菌(Hp)根除率及不良反应发生情况。结果干预组患者PU临床症状疗效、胃镜复查PU愈合治疗总有效率高于对照组,差异有统计学意义(P<0.05)。干预组患者Hp根除率高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论康复新液联合泮托拉唑三联疗法治疗PU的临床疗效明显,可提高溃疡的愈合率,改善症状,优于单独使用泮托拉唑三联疗法。
Objective To investigate the clinical efficacy of Kangfuxin solution combined with pantoprazole triple therapy in the treatment of peptic ulcer (PU). Methods 100 cases of PU patients admitted to Shangrao People’s Hospital from September to December in 2015 were selected. Randomly divided into control group and intervention group, 50 cases each. The control group was treated with pantoprazole, clarithromycin and amoxicillin, and the intervention group was given Kangfuxin solution on the basis of the control group. The clinical efficacy of PU in both groups was compared, PU healing of gastroscopy, the eradication rate of Helicobacter pylori (Hp) and the incidence of adverse reactions were compared. Results The clinical efficacy of PU in intervention group was higher than that in control group (P <0.05). Hp eradication rate in the intervention group was higher than that in the control group, the difference was statistically significant (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Kangfuxin solution combined with pantoprazole triple therapy significantly improved the clinical efficacy of PU, which can improve the healing rate of ulcers and improve symptoms, superior to the single use of pantoprazole triple therapy.